Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-06-14

Clinical Trial Update: Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and activity of HE3286 in patients with Type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HE3286

Snippet

Sponsor: Harbor Therapeutics | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED